



IABS 2nd Meeting on Advances in Analytical Technologies for Biopharmaceutical Products

March 19-21, 2025

Universities of MD at Shady Grove, Rockville, MD

Advances in analytical technologies help drive progress in the development and manufacturing of biopharmaceutical products. Improved analytical technologies enable better identification of relevant critical quality attributes, help assure product quality, advance non-clinical studies, identify biomarkers/diagnostics, and increase general knowledge of products and processes. This IABS Meeting will bring together scientists from academia, industry, government, and other organizations for in-depth exploration of the latest cutting-edge advances in analytical technologies for developing biopharmaceutical products ranging from monoclonal antibody therapeutics to new modalities such as viral vector mediated gene therapies and vaccines, mRNA vaccines, and adoptive cell therapies. Tentative sessions include: 1) Analytical technologies for novel modalities such as cell and gene therapies and mRNA products; 2) Analytical technologies for monitoring process and product quality; 3) New tools for bioassays and immunogenicity assays; 4) Novel standards for advancing analytical technologies; and 5) Next generation analytical technologies utilizing AI, supporting non-clinical studies, and biomarker/diagnostic development.

SCIENTIFIC COMMITTEE

- **Mark SCHENERMAN** – UMBC, Co-Chair
- **Michael TARLOV** – NIST, Co-Chair
- **Shawn NOVICK** – IABS Chair
- **Christopher BRAVERY** – IABS
- **Michael BRENOWITZ** – Albert Einstein College of Medicine
- **William DALL'ACQUA** – Meso Scale Diagnostics
- **Pieter NEELS** – IABS
- **Niomi PECKHAM** – US Pharmacopeia
- **Jonathan J. PHILIPS** – University of Exeter
- **Nadine RITTER** – Global Biotech Experts
- **Sarah ROGSTAD** – FDA
- **Mehmet TOSUN** – UMBC

PROVISIONAL AGENDA

DAY 1 – WEDNESDAY 19 OF MARCH, 2025

SESSION 1 – Novel technologies for supporting non-clinical studies and diagnostics development

SESSION 2 – Novel analytics for emerging modalities (Part 1)

DAY 2 – THURSDAY 20 OF MARCH, 2025

SESSION 3 – Novel analytics for emerging modalities (Part 2)

SESSION 4A - Advances in bioassays (CGT, mechanism-based potency)

SESSION 4B - Gaps in current analytical technologies

DAY 3 – FRIDAY 21 OF MARCH, 2025

SESSION 5 – Translating novel technologies toward routine implementation